Results 181 to 190 of about 6,777,214 (229)
Some of the next articles are maybe not open access.
neurogenetics, 2021
Congenital insensitivity to pain with anhidrosis (CIPA) is a rare autosomal recessive disease resulting from mutations in the NTRK1 gene encoding the neurotrophic tyrosine kinase-1 receptor. In this multicenter observational retrospective study, we investigated CIPA patients identified from French laboratories sequencing the NTRK1 gene, and seven ...
A. Echaniz-Laguna +11 more
semanticscholar +3 more sources
Congenital insensitivity to pain with anhidrosis (CIPA) is a rare autosomal recessive disease resulting from mutations in the NTRK1 gene encoding the neurotrophic tyrosine kinase-1 receptor. In this multicenter observational retrospective study, we investigated CIPA patients identified from French laboratories sequencing the NTRK1 gene, and seven ...
A. Echaniz-Laguna +11 more
semanticscholar +3 more sources
A multicolor immunosensor for point-of-care testing NTRK1 gene fusion
Sensors and Actuators B: Chemical, 2021Abstract The gene fusion of Neurotrophic tropomyosin receptor kinase (NTRK) promotes the formation of tumors and is closely related to multiple cancers. Therefore, the detection of NTRK gene fusion markers has been a research hotspot in recent years.
Lishuang Yu +7 more
semanticscholar +2 more sources
TRKA expression and NTRK1 gene copy number across solid tumours
Journal of Clinical Pathology, 2018Aims Neurotrophic Tropomyosin Kinase Receptor 1 (NTRK1) gene encodes for the protein Tropomyosin-related kinase A (TRKA). Deregulated activity of TRKA has been shown to have oncogenic potential. We present here the results of an immunohistochemical (IHC) observational cohort study of TRKA expression together with ...
G. Mauri +21 more
semanticscholar +4 more sources
Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma.
Cancer Letters, 2015Chromosomal rearrangements of the NTRK1 gene, which encodes the high affinity nerve growth factor receptor (tropomyosin related kinase, TRKA), have been observed in several epithelial cancers, such as colon cancer, papillary thyroid carcinoma or non small cell lung cancer.
L. Créancier +8 more
semanticscholar +3 more sources
NTRK1 gene fusions as a novel oncogene target in lung cancer.
Journal of Clinical Oncology, 20138023 Background: The identification and therapeutic targeting of oncogenic drivers in lung adenocarcinoma has led to significant clinical improvements for patients with EGFR mutations or ALK fusions. However, many lung cancer patients do not yet have an identified oncogenic driver and the discovery of new actionable oncogenic drivers is thus an ...
R. Doebele +14 more
semanticscholar +2 more sources
Abstract 4265: Identification of new NTRK1 gene fusion as oncogene target in colon cancer
Cancer Research, 2015Abstract In an effort to better characterize the activity of a multi-kinase inhibitors, antiproliferative activity was evaluated against a panel of human tumor cell lines. Among the different cell lines tested we have been able to highlight that the KM12 human colorectal carcinoma present hypersensitivity to inhibition.
L. Créancier +7 more
semanticscholar +2 more sources
A new mutation in NTRK1 gene is associated with congenital insensitivity to pain without anhidrosis
Meta Gene, 2019Abstract Congenital insensitivity to pain with anhidrosis (CIPA) is a very rare autosomal recessive disease characterized by pain insensitivity, frequent intermittent fevers, anhidrosis, self-mutilating actions and mental retardation. Germline mutations in NTRK1 gene have been associated with CIPA. In the current study, we describe the first reported
Mogge Hajiesmaeil +3 more
semanticscholar +2 more sources
Abstract IA41: A new TRacK in lung cancer: NTRK1 gene fusions as a therapeutic target.
Clinical Cancer Research, 2014Abstract Non-small cell lung cancer (NSCLC) is a heterogeneous disease that can be organized into groups designated by the dominant oncogene or oncogenic ‘driver’. Classification of NSCLC by oncogenes is critical because oral kinase inhibitors or other targeted therapeutic strategies can often effectively inhibit these oncogenes leading ...
R. Doebele
semanticscholar +2 more sources

